On May, 8 Aclaris Therapeutics, Inc. (ACRS) Analysts See $-0.97 EPS

April 16, 2018 - By Michele Cranor

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Corporate Logo

Investors wait Aclaris Therapeutics, Inc. (NASDAQ:ACRS)’s quarterly earnings on May, 8., RTT reports. Last year’s EPS was $-0.48, while now analysts expect change of 102.08 % down from current $-0.97 EPS. Wall Street sees 21.25 % negative EPS growth as of May, 8. ACRS reached $17.78 on during the last trading session after $0.16 change.Currently Aclaris Therapeutics, Inc. is downtrending after 45.27% change in last April 16, 2017. ACRS has 183,844 shares volume. ACRS underperformed the S&P 500 by 56.82%.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology.The firm is worth $549.43 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor.Last it reported negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: